Literature DB >> 20308562

Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds.

Sabyasachi Biswas1, Sashwati Roy, Jaideep Banerjee, Syed-Rehan A Hussain, Savita Khanna, Guruguhan Meenakshisundaram, Periannan Kuppusamy, Avner Friedman, Chandan K Sen.   

Abstract

Ischemia complicates wound closure. Here, we are unique in presenting a murine ischemic wound model that is based on bipedicle flap approach. Using this model of ischemic wounds we have sought to elucidate how microRNAs may be implicated in limiting wound re-epithelialization under hypoxia, a major component of ischemia. Ischemia, evaluated by laser Doppler as well as hyperspectral imaging, limited blood flow and lowered tissue oxygen saturation. EPR oximetry demonstrated that the ischemic wound tissue had pO(2) <10 mm Hg. Ischemic wounds suffered from compromised macrophage recruitment and delayed wound epithelialization. Specifically, epithelial proliferation, as determined by Ki67 staining, was compromised. In vivo imaging showed massive hypoxia inducible factor-1alpha (HIF-1alpha) stabilization in ischemic wounds, where HIF-1alpha induced miR-210 expression that, in turn, silenced its target E2F3, which was markedly down-regulated in the wound-edge tissue of ischemic wounds. E2F3 was recognized as a key facilitator of cell proliferation. In keratinocytes, knock-down of E2F3 limited cell proliferation. Forced stabilization of HIF-1alpha using Ad-VP16- HIF-1alpha under normoxic conditions up-regulated miR-210 expression, down-regulated E2F3, and limited cell proliferation. Studies using cellular delivery of miR-210 antagomir and mimic demonstrated a key role of miR-210 in limiting keratinocyte proliferation. In summary, these results are unique in presenting evidence demonstrating that the hypoxia component of ischemia may limit wound re-epithelialization by stabilizing HIF-1alpha, which induces miR-210 expression, resulting in the down-regulation of the cell-cycle regulatory protein E2F3.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308562      PMCID: PMC2872456          DOI: 10.1073/pnas.1001653107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Differentiation and injury-repair signals modulate the interaction of E2F and pRB proteins with novel target genes in keratinocytes.

Authors:  Wing Y Chang; Joseph Andrews; David E Carter; Lina Dagnino
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

2.  The use of medical hyperspectral technology to evaluate microcirculatory changes in diabetic foot ulcers and to predict clinical outcomes.

Authors:  Lalita Khaodhiar; Thanh Dinh; Kevin T Schomacker; Svetlana V Panasyuk; Jenny E Freeman; Robert Lew; Tiffany Vo; Alexander A Panasyuk; Christina Lima; John M Giurini; Thomas E Lyons; Aristidis Veves
Journal:  Diabetes Care       Date:  2007-02-15       Impact factor: 19.112

3.  Human skin wounds: a major and snowballing threat to public health and the economy.

Authors:  Chandan K Sen; Gayle M Gordillo; Sashwati Roy; Robert Kirsner; Lynn Lambert; Thomas K Hunt; Finn Gottrup; Geoffrey C Gurtner; Michael T Longaker
Journal:  Wound Repair Regen       Date:  2009 Nov-Dec       Impact factor: 3.617

4.  Transcutaneous PO2 measurements in health and peripheral arterial occlusive disease.

Authors:  U K Franzeck; P Talke; E F Bernstein; F L Golbranson; A Fronek
Journal:  Surgery       Date:  1982-02       Impact factor: 3.982

5.  Sustained (rh)VEGF(165) release from a sprayed fibrin biomatrix induces angiogenesis, up-regulation of endogenous VEGF-R2, and reduces ischemic flap necrosis.

Authors:  Rainer Mittermayr; Tatjana Morton; Martina Hofmann; Sam Helgerson; Martijn van Griensven; Heinz Redl
Journal:  Wound Repair Regen       Date:  2008 Jul-Aug       Impact factor: 3.617

6.  Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

Authors:  Richard J Powell; Michael Simons; Farrel O Mendelsohn; George Daniel; Timothy D Henry; Minako Koga; Ryuichi Morishita; Brian H Annex
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

7.  Oxygen inhalation--induced transcutaneous PO2 changes as a predictor of amputation level.

Authors:  T R Harward; J Volny; F Golbranson; E F Bernstein; A Fronek
Journal:  J Vasc Surg       Date:  1985-01       Impact factor: 4.268

8.  Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing.

Authors:  Chandan K Sen; Savita Khanna; Bernard M Babior; Thomas K Hunt; E Christopher Ellison; Sashwati Roy
Journal:  J Biol Chem       Date:  2002-06-14       Impact factor: 5.157

9.  Skin flap research: a candid view.

Authors:  C L Kerrigan; R K Daniel
Journal:  Ann Plast Surg       Date:  1984-11       Impact factor: 1.539

10.  miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer.

Authors:  Antonis Giannakakis; Raphael Sandaltzopoulos; Joel Greshock; Shun Liang; Jia Huang; Kosei Hasegawa; Chunsheng Li; Ann O'Brien-Jenkins; Dionyssios Katsaros; Barbara L Weber; Celeste Simon; George Coukos; Lin Zhang
Journal:  Cancer Biol Ther       Date:  2007-11-14       Impact factor: 4.742

View more
  129 in total

1.  A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts.

Authors:  R Faraonio; P Salerno; F Passaro; C Sedia; A Iaccio; R Bellelli; T C Nappi; M Comegna; S Romano; G Salvatore; M Santoro; F Cimino
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

Review 2.  MicroRNAs in skin and wound healing.

Authors:  Jaideep Banerjee; Yuk Cheung Chan; Chandan K Sen
Journal:  Physiol Genomics       Date:  2010-10-19       Impact factor: 3.107

3.  miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells.

Authors:  Yuk Cheung Chan; Savita Khanna; Sashwati Roy; Chandan K Sen
Journal:  J Biol Chem       Date:  2010-11-16       Impact factor: 5.157

Review 4.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

5.  Aging impairs the mobilization and homing of bone marrow-derived angiogenic cells to burn wounds.

Authors:  Xianjie Zhang; Kakali Sarkar; Sergio Rey; Raul Sebastian; Efstathia Andrikopoulou; Guy P Marti; Karen Fox-Talbot; Gregg L Semenza; John W Harmon
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

6.  Mixed-species biofilm compromises wound healing by disrupting epidermal barrier function.

Authors:  Sashwati Roy; Haytham Elgharably; Mithun Sinha; Kasturi Ganesh; Sarah Chaney; Ethan Mann; Christina Miller; Savita Khanna; Valerie K Bergdall; Heather M Powell; Charles H Cook; Gayle M Gordillo; Daniel J Wozniak; Chandan K Sen
Journal:  J Pathol       Date:  2014-05-27       Impact factor: 7.996

Review 7.  microRNA-200b as a Switch for Inducible Adult Angiogenesis.

Authors:  Mithun Sinha; Subhadip Ghatak; Sashwati Roy; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2015-05-10       Impact factor: 8.401

Review 8.  The Role of Hypoxia-Inducible Factor in Wound Healing.

Authors:  Wan Xing Hong; Michael S Hu; Mikaela Esquivel; Grace Y Liang; Robert C Rennert; Adrian McArdle; Kevin J Paik; Dominik Duscher; Geoffrey C Gurtner; H Peter Lorenz; Michael T Longaker
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-05-01       Impact factor: 4.730

Review 9.  Regulation of cell proliferation by hypoxia-inducible factors.

Authors:  Maimon E Hubbi; Gregg L Semenza
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-21       Impact factor: 4.249

10.  MicroRNAs in Hypoxia Response.

Authors:  Simona Greco; Fabio Martelli
Journal:  Antioxid Redox Signal       Date:  2014-09-10       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.